These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 27160425)
21. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Nachum Z; Shupak A; Gordon CR Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539 [TBL] [Abstract][Full Text] [Related]
22. Anticholinergic Versus Antihistaminic Treatment for Simulator Sickness Prevention. Ben-Ari O; Sarfati S; Gordon B; Assa A; Nakdimon I J Clin Pharmacol; 2023 Oct; 63(10):1119-1125. PubMed ID: 37491788 [TBL] [Abstract][Full Text] [Related]
23. Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Chapotot F; Pigeau R; Canini F; Bourdon L; Buguet A Psychopharmacology (Berl); 2003 Mar; 166(2):127-38. PubMed ID: 12552359 [TBL] [Abstract][Full Text] [Related]
24. Side effects of antimotion sickness drugs. Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702 [TBL] [Abstract][Full Text] [Related]
25. Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Saletu B; Frey R; Krupka M; Anderer P; Grünberger J; Barbanoj MJ Int J Clin Pharmacol Res; 1989; 9(3):183-95. PubMed ID: 2568348 [TBL] [Abstract][Full Text] [Related]
26. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine. Simon P; Panissaud C; Costentin J Psychopharmacology (Berl); 1994 May; 114(4):597-600. PubMed ID: 7855221 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Pérez-Mañá C; Castells X; Torrens M; Capellà D; Farre M Cochrane Database Syst Rev; 2013 Sep; (9):CD009695. PubMed ID: 23996457 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of antimotion sickness drug side effects on performance. Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169 [TBL] [Abstract][Full Text] [Related]
31. Modafinil alone and in combination with low dose amphetamine does not establish conditioned place preference in male Sprague-Dawley rats. Quisenberry AJ; Prisinzano TE; Baker LE Exp Clin Psychopharmacol; 2013 Jun; 21(3):252-8. PubMed ID: 23647093 [TBL] [Abstract][Full Text] [Related]
32. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests. Suri KB; Crampton GH; Daunton NG Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness and duration of intramuscular antimotion sickness medications. Wood CD; Stewart JJ; Wood MJ; Mims M J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161 [TBL] [Abstract][Full Text] [Related]
34. Prevalence, Predictors, and Prevention of Motion Sickness in Zero-G Parabolic Flights. Golding JF; Paillard AC; Normand H; Besnard S; Denise P Aerosp Med Hum Perform; 2017 Jan; 88(1):3-9. PubMed ID: 28061915 [TBL] [Abstract][Full Text] [Related]
35. Transdermal scopolamine in the prevention of motion sickness at sea. Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021 [TBL] [Abstract][Full Text] [Related]